2023-11-14T14:06:11-08:00 2022-12-31 472626541 Cook & Company A Prof Actcy Corporation One Sansome St Ste 3500 San Francisco CA 94104 990 2022-01-01 261721868 Addario Lung Cancer Medical Institute ADDA 6505982857 1100 Industrial Road Suite 1 San Carlos CA 94070 Tony Addario CEO 2023-11-14 true Tony Addario 999009999 true Douglas Cook PhDMPACPA P01521705 4156211112 3 AAL1 IAL1 FAL1 2022 2023-04-26 12:10:37Z Tony Addario 1061978 false X www.ALCMI.net X 2008 CA The Addario Lung Cancer Medical Institute ALCMI is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment opetions for lung cancer patients. 6 6 1 0 876750 622909 676747 438979 147 90 0 1553644 1061978 0 0 328450 348003 0 30505 757916 639669 1086366 987672 467278 74306 1036268 1003534 178466 71426 857802 932108 The Addario Lung Cancer Medical Institute ALCMI is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment opetions for lung cancer patients. false false 843051 438979 Research - The Addario Lung Cancer Medical Institute (ALCMI) is dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. ALCMI is a patient-founded, patient-focused research consortium. Its goal is to make lung cancer a chronically managed disease. ALCMI was created in 2008, and as a partner organization today with Go2 for Lung Cancer Foundation (Wash DC), to enable the collection and analysis of tissue and blood samples which are essential to research and to the development of individually tailored (and more effective) therapies. ALCMI is also a comprehensively contracted consortium with shared infrastructures (standardized contracts, data systems and biorepositories) and centrally coordinated scientific planning. (Cont'd. at Schedule O) 843051 true true false false false false false false false false true false false false true false true false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false true 6 0 true 1 true false false false false false false false 0 false false false false false false false X 6 6 true false false false false false false true false false false true true true true true true false true false CA X Debi Beltramo 6505982857 1100 Industrial Road Suite 1 San Carlos CA 94070 X Richard Erwin Senior Dir. Clinical Operations 40.00 0.00 202470 0 8967 Tony Addario Chair CEO 40.00 0.00 X X 0 0 0 Sam Bain Treasurer Director 0.46 0.00 X X 0 0 0 Bonnie Addario Director 5.00 0.00 X 0 0 0 Bruce Gellman Director 0.46 0.00 X 0 0 0 Pankaj Patel Director 0.46 0.00 X 0 0 0 Ignacio Del Rio Director 0.46 0.00 X 0 0 0 202470 8967 1 false true false Harper Clinical Res SrvcsLLC 53 Stono Drive Greenville SC 29609 Clinical consultants 216000 1 622909 622909 Fees for Services 900099 438979 438979 438979 90 90 0 0 0 0 0 0 0 0 1061978 438979 90 X 0 0 0 0 212253 178293 33960 0 99004 54256 21128 23620 0 16951 9523 3606 3822 19795 14557 3431 1807 0 295 295 36509 36509 0 0 0 523330 522275 1055 0 13492 12360 1132 0 0 21120 21120 9422 8929 493 0 0 0 0 0 19588 19588 Miscellaneous 15913 13537 2246 130 Shared cost allocation 0 29321 -30447 1126 0 987672 843051 114116 30505 0 909918 913338 0 60581 50385 0 0 0 0 65372 12104 3595 3595 397 0 0 0 0 0 27707 1036268 1003534 133381 43719 45085 27707 178466 71426 X 857802 932108 857802 932108 1036268 1003534 74306 X false true X true false X 1322778 888650 745843 876750 622909 4456930 0 0 1322778 888650 745843 876750 622909 4456930 240058 4216872 60 149 122 147 90 568 0 36622 4449 41071 4498569 1540010 0.93740 0.94330 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 3595 3595 Lease liabilities 27707 27707 1061978 1061978 1061978 987672 987672 987672 false false false false false false false false false Richard Erwin Senior Dir. Clinical Operations 202470 8967 211437 Tony Addario CEO/Chair 21120 Office rent false Schedule L, Part V Supplemental Information Tony Addario, Chair/CEO, of filing entity has a beneficial interest in Brittan Avenue, LLC, which is the landlord of the filing entity. Form 990, Part VI, Section A, Line 2 Tony Addario, Chair and CEO, is husband of Bonnie Addario, Director. Director Sam Bain is a finanical advisor to Bonnie and Tony Addario. Form 990, Part VI, Section B, Line 11b An electronic copy of Form 990 is provided to the Board of Directors for review before filing. Form 990, Part VI, Section B, Line 12c The Conflict of Interest Committee is a standing committee and shall consist of no fewer than three directors. The Conflict of Interest Committee is responsible for identifying, investigating and advising the Board with respect to existing and/or potential transactions that may benefit the private interest of a director or Officer of the Corporation in accordance with the Conflict of Interest Policy of the Corporation annexed to the by-laws as Annex A, interpreting the Conflicts of Interest Policy, reporting to the Board on its actions no less than annually, and conducting periodic reviews of the Corporation's activities to identify potential and/or actual Interested Party transactions. Subject to the provisions of this Section 5.4 and Annex A, the Conflict of Interest Committee shall have such additional purpose, membership, general and specific functions and responsibilities as may be provided for in any committee charter of the Conflict of Interest Committee approved by the entire Board. Form 990, Part VI, Section B, Line 15b ALCMI's CEO is not compensated. Regarding the compensation paid to the Senior Director of Clinical Operations, the CEO conducts reviews, checks Non Profit compensation reports from CA NonProfits. The board also reviews. This process occurred during 2020. Form 990, Part VI, Section C, Line 19 The Organization shall make available its governing documents, conflict of interest policy and financial statements upon request. Form 990, Part III, 4a- Program Expenses (Cont'd. from page 2) ALCMI's researchers are pooling their knowledge, specimens and data in order to improve the understanding of the molecular bases of lung cancer and to accelerate the development and delivery of much more effective, targeted drugs and treatments tailored to individual patient types. ALCMI has developed and launched a number of innovative research studies that would otherwise not have existed: 1) CASTLE: a prospective, longitudinal, multi-center study with serial biobanked advanced stage lung cancer specimens that are also annotated with clinical/molecular data. 2) INHERIT EGFR T790M: a prospective study on germline biology in high-risk families; to identify specific inherited genetic markers indicating risk of developing lung cancer, and 3) Genomics of Young Lung Cancer (GoYLC): a prospectively performed comprehensive genomic profiling to determine whether young lung cancers harbor a distinctive spectrum of genetic mutations, and therefore unique treatment strategies (peer-reviewed paper published in 2021, Journal of Thoracic Oncology). Other studies in progress are 1) Epidemiology of Young Lung Cancer (EoYLC): a remote decentralized survey study designed to identify lifestyle, environmental, and family/genetic risk factors associated with the development of lung cancer under the age of 50, and any possible connection to specific cancer-driving mutations. 2) SPACEWALK: a study to investigate the relationship between specific ALK resistance mutations and specific next generation ALK TKI therapies received before progression (peer-reviewed paper published in 2021, Journal of Thoracic Oncology). 3) BEACON-LUNG: a multicenter study collecting serum, plasma, tissue, and CT images from patients receiving pembrolizumab or pembrolizumab plus carboplatin-based chemotherapy to help identify patients who may benefit from a more aggressive triplet treatment regimen. This test utilizes mass spectrometry with machine learning and was developed by Biodesix, Inc. to classify patients as responders or non-responders, which could help identify patients who may benefit from a triplet treatment regimen. 4) ENIGMA+: a remote decentralized study collecting tissue and sputum specimens and clinical outcome data across patients diagnosed with ALK+ mutation NSCLC. 5) SPARK: a remote decentralized study collecting blood specimens and clinical outcome data across patients diagnosed with KRAS mutation NSCLC.